PMC:7228307 / 2784-3046 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"35","span":{"begin":12,"end":33},"obj":"Disease"},{"id":"36","span":{"begin":46,"end":53},"obj":"Disease"},{"id":"37","span":{"begin":84,"end":96},"obj":"Disease"}],"attributes":[{"id":"A35","pred":"tao:has_database_id","subj":"35","obj":"MESH:D007249"},{"id":"A36","pred":"tao:has_database_id","subj":"36","obj":"MESH:D009369"},{"id":"A37","pred":"tao:has_database_id","subj":"37","obj":"MESH:D009369"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":" of chronic inflammatory diseases and of some cancers including otherwise incurable malignancies.1 They are commercially important and in 2017, five mAbs collectively grossed $45.6 billion in sales, placing them in the top ten drugs globally.2 MAb development is"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T8","span":{"begin":12,"end":33},"obj":"Disease"}],"attributes":[{"id":"A8","pred":"mondo_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/MONDO_0021166"}],"text":" of chronic inflammatory diseases and of some cancers including otherwise incurable malignancies.1 They are commercially important and in 2017, five mAbs collectively grossed $45.6 billion in sales, placing them in the top ten drugs globally.2 MAb development is"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T32","span":{"begin":223,"end":226},"obj":"http://purl.obolibrary.org/obo/CLO_0050884"}],"text":" of chronic inflammatory diseases and of some cancers including otherwise incurable malignancies.1 They are commercially important and in 2017, five mAbs collectively grossed $45.6 billion in sales, placing them in the top ten drugs globally.2 MAb development is"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T9","span":{"begin":192,"end":197},"obj":"Chemical"},{"id":"T10","span":{"begin":227,"end":232},"obj":"Chemical"}],"attributes":[{"id":"A9","pred":"chebi_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/CHEBI_24866"},{"id":"A10","pred":"chebi_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"}],"text":" of chronic inflammatory diseases and of some cancers including otherwise incurable malignancies.1 They are commercially important and in 2017, five mAbs collectively grossed $45.6 billion in sales, placing them in the top ten drugs globally.2 MAb development is"}

{"project":"LitCovid-sample-PD-IDO","denotations":[{"id":"T14","span":{"begin":25,"end":33},"obj":"http://purl.obolibrary.org/obo/OGMS_0000031"}],"text":" of chronic inflammatory diseases and of some cancers including otherwise incurable malignancies.1 They are commercially important and in 2017, five mAbs collectively grossed $45.6 billion in sales, placing them in the top ten drugs globally.2 MAb development is"}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"35","span":{"begin":12,"end":33},"obj":"Disease"},{"id":"36","span":{"begin":46,"end":53},"obj":"Disease"},{"id":"37","span":{"begin":84,"end":96},"obj":"Disease"}],"attributes":[{"id":"A35","pred":"pubann:denotes","subj":"35","obj":"MESH:D007249"},{"id":"A36","pred":"pubann:denotes","subj":"36","obj":"MESH:D009369"},{"id":"A37","pred":"pubann:denotes","subj":"37","obj":"MESH:D009369"}],"text":" of chronic inflammatory diseases and of some cancers including otherwise incurable malignancies.1 They are commercially important and in 2017, five mAbs collectively grossed $45.6 billion in sales, placing them in the top ten drugs globally.2 MAb development is"}

{"project":"LitCovid-sample-PD-MONDO","denotations":[{"id":"T6","span":{"begin":12,"end":33},"obj":"Disease"}],"attributes":[{"id":"A6","pred":"mondo_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/MONDO_0021166"}],"text":" of chronic inflammatory diseases and of some cancers including otherwise incurable malignancies.1 They are commercially important and in 2017, five mAbs collectively grossed $45.6 billion in sales, placing them in the top ten drugs globally.2 MAb development is"}